Skip to main content

Table 1 Demographics and HRQOL/clinical findings of the study participants (n = 122)

From: Validation of the japanese version of the sarcoidosis health questionnaire: A cross-sectional study

  Mean ± SD or n (%) Range
Age, years 56.8 ± 15.5 24 - 85
Female 74 (60.6%)  
Duration of sarcoidosis (months) 108.9 ± 86.2 2 - 395
Number of organ systems involved 1.8 ± 0.8 1 - 5
Radiographic stage 37/32/33/15/5  
(0/I/II/III/IV) (30.3%/26.2%/27.0%/12.3%/4.1%)
Blood laboratory tests   
   ACE, IU/L 17.2 ± 6.5 3.8 - 41.7
   sIL-2R, IU/mL 639.9 ± 507.5 128 - 3772
Pulmonary function tests   
   FVC, %predicted 105.8 ± 18.5 44.3 - 146.4
   FEV1, %predicted 105.8 ± 21.0 35.0 - 158.7
   DLCO, %predicted 85.1 ± 17.2 33.7 - 133.3
Echocardiogram   
   LVEF, % 68.1 ± 11.4 31.8 - 79.5
   PASP, mmHg 29.4 ± 5.9 19.0 - 57.4
SHQ   
   Daily Functioning [17] 4.7 ± 1.0 2.1 - 6.7
   Physical Functioning [17] 5.4 ± 1.0 2.7 - 6.8
   Emotional Functioning [17] 4.8 ± 1.0 2.2 - 6.9
   Total [17] 4.9 ± 0.9 2.4 - 6.7
SF-36   
   Physical functioning [0-100] 79.2 ± 20.9 0 - 100
   Role-physical [0-100] 77.1 ± 27.0 0 - 100
   Bodily pain [0-100] 71.9 ± 26.7 0 - 100
   General health perceptions [0-100] 50.0 ± 19.7 0 - 97
   Vitality [0-100] 52.2 ± 23.1 0 - 100
   Social functioning [0-100] 78.6 ± 24.1 0 - 100
   Role-emotional [0-100] 77.7 ± 25.7 0 - 100
   Mental health [0-100] 66.6 ± 20.5 5 - 100
SGRQ   
   Symptoms [0-100] 39.8 ± 20.6 0 - 86.5
   Activity [0-100] 29.7 ± 24.9 0 - 92.5
   Impact [0-100] 14.6 ± 14.6 0 - 57.3
   Total [0-100] 23.4 ± 16.3 0 - 71.8
MRC [15] 1.8 ± 0.8 1 - 5
CES-D [0-60] 12.8 ± 9.3 0 - 45
  1. The numbers in square brackets represent the theoretical score range.
  2. On the SHQ and SF-36, higher scores indicate better status, while on the SGRQ, MRC, CES-D, lower scores indicate better status.
  3. Abbreviations: HRQOL, health-related quality of life; SD, standard deviation; ACE, angiotensin-converting enzyme; sIL-2R, soluble interleukin-2 receptor; FVC, forced vital capacity; FEV1, forced expiratory volume in one second; DLCO, diffusion capacity for carbon monoxide; LVEF, left ventricular ejection fraction; PASP, pulmonary arterial systolic pressure SHQ, Sarcoidosis Health Questionnaire; SF-36, Medical Outcomes Study 36-item short form; SGRQ, St. George's Respiratory Questionnaire; MRC, Medical Research Council; CES-D, Center for Epidemiologic Study-Depression Scale